Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in Nat Med Retrieve available abstracts of 34 articles: HTML format

Single Articles

October 2025
1. LONG GV, Garnett-Benson C, Dolfi S, Ascierto PA, et al
   Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
   Nat Med. 2025 Oct 18. doi: 10.1038/s41591-025-04032.
   PubMed     Abstract available
   
   
   September 2025
2. LONG GV, Nair N, Marbach D, Scolyer RA, et al
   Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
   Nat Med. 2025 Sep 24. doi: 10.1038/s41591-025-03967.
   PubMed     Abstract available
   
   
   August 2025
3. KENDRA KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, et al
   Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
   Nat Med. 2025 Aug 26. doi: 10.1038/s41591-025-03975.
   PubMed    
   
   
   
4. KENDRA KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, et al
   Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
   Nat Med. 2025 Aug 14. doi: 10.1038/s41591-025-03875.
   PubMed     Abstract available
   
   
   
5. BORGERS JSW, Lenkala D, Kohler V, Jackson EK, et al
   Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
   Nat Med. 2025 Aug 4. doi: 10.1038/s41591-025-03896.
   PubMed    
   
   
   
6. MIGLINO N, Toussaint NC, Ring A, Bonilla X, et al
   Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
   Nat Med. 2025 Aug 1. doi: 10.1038/s41591-025-03904.
   PubMed    
   
   
   
7. YAN S, Yu Z, Primiero C, Vico-Alonso C, et al
   A multimodal vision foundation model for clinical dermatology.
   Nat Med. 2025;31:2691-2702.
   PubMed     Abstract available
   
   
   July 2025
8. MILOTAY G, Little M, Watson RA, Muldoon D, et al
   CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
   Nat Med. 2025;31:2350-2364.
   PubMed     Abstract available
   
   
   
9. WERMKE M, Araujo DM, Chatterjee M, Tsimberidou AM, et al
   Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial.
   Nat Med. 2025;31:2365-2374.
   PubMed     Abstract available
   
   
   June 2025
10. MONSON KR, Ferguson R, Handzlik JE, Morales L, et al
    Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
    Nat Med. 2025 Jun 5. doi: 10.1038/s41591-025-03699.
    PubMed     Abstract available
    
    
    May 2025
11. MIGLINO N, Toussaint NC, Ring A, Bonilla X, et al
    Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
    Nat Med. 2025 May 27. doi: 10.1038/s41591-025-03715.
    PubMed     Abstract available
    
    
    January 2025
12. DUMMER R, Robert C, Scolyer RA, Taube JM, et al
    Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
    Nat Med. 2025 Jan 7. doi: 10.1038/s41591-024-03411.
    PubMed     Abstract available
    
    
    
13. BORGERS JSW, Lenkala D, Kohler V, Jackson EK, et al
    Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
    Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03418.
    PubMed     Abstract available
    
    
    June 2024
14. LONG GV, Carlino MS, Au-Yeung G, Spillane AJ, et al
    Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
    Nat Med. 2024 Jun 21. doi: 10.1038/s41591-024-03077.
    PubMed     Abstract available
    
    
    
15. O'LEARY K
    Neoadjuvant immunotherapy a new standard of care for melanoma.
    Nat Med. 2024 Jun 17. doi: 10.1038/d41591-024-00045.
    PubMed    
    
    
    February 2024
16. BJORK JR, Bolte LA, Maltez Thomas A, Lee KA, et al
    Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
    Nat Med. 2024 Feb 16. doi: 10.1038/s41591-024-02803.
    PubMed     Abstract available
    
    
    January 2024
17. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
    PubMed    
    
    
    
18. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2024 Jan 4. doi: 10.1038/s41591-023-02775.
    PubMed    
    
    
    November 2023
19. FRATERMAN I, Reijers ILM, Dimitriadis P, Broeks A, et al
    Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02631.
    PubMed     Abstract available
    
    
    
20. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02650.
    PubMed    
    
    
    
21. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02661.
    PubMed    
    
    
    October 2023
22. KIRKWOOD J, Del Vecchio M, Weber J, Hoeller C, et al
    Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02583.
    PubMed     Abstract available
    
    
    August 2023
23. VANDERWALDE A, Bellasea SL, Kendra KL, Khushalani NI, et al
    Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
    Nat Med. 2023 Aug 17. doi: 10.1038/s41591-023-02498.
    PubMed     Abstract available
    
    
    
24. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    PubMed    
    
    
    
25. BARATA C, Rotemberg V, Codella NCF, Tschandl P, et al
    A reinforcement learning model for AI-based decision support in skin cancer.
    Nat Med. 2023;29:1941-1946.
    PubMed     Abstract available
    
    
    July 2023
26. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02453.
    PubMed     Abstract available
    
    
    
27. BRASTIANOS PK, Kim AE, Giobbie-Hurder A, Lee EQ, et al
    Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
    Nat Med. 2023;29:1728-1737.
    PubMed     Abstract available
    
    
    May 2023
28. GARBE C, Dummer R, Amaral T, Amaria RN, et al
    Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
    Nat Med. 2023 May 16. doi: 10.1038/s41591-023-02336.
    PubMed    
    
    
    April 2023
29. LIU S, Dharanipragada P, Lomeli SH, Wang Y, et al
    Multi-organ landscape of therapy-resistant melanoma.
    Nat Med. 2023 Apr 27. doi: 10.1038/s41591-023-02304.
    PubMed     Abstract available
    
    
    
30. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    PubMed     Abstract available
    
    
    March 2023
31. O'LEARY K
    Earlier appears better for immunotherapy in melanoma.
    Nat Med. 2023 Mar 16. doi: 10.1038/d41591-023-00028.
    PubMed    
    
    
    
32. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    PubMed     Abstract available
    
    
    February 2023
33. TIAN J, Chen JH, Chao SX, Pelka K, et al
    Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial.
    Nat Med. 2023;29:458-466.
    PubMed     Abstract available
    
    
    
34. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.